Sign up
Pharma Capital

MaxCyte's Doug Doerfler 'confident of providing long-term treatment' for CGD patients

Doug Doerfler, president and chief executive of MaxCyte, Inc. (LON:MXCT) tells Proactive they're to continue their collaboration with one of the world’s leading infectious disease institutes after signing a cooperative research and development agreement with the US National Institute of Allergy and Infectious Diseases (NIAD).

The two will work together to explore the development of new therapies for X-linked chronic granulomatous disease (CGD) using MaxCyte’s Flow Electroporation gene-correction platform.

 

View full MXCT profile

MaxCyte Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.